SAN FRANCISCO — A randomized study involving 30 participants published in JAMA Network Open identified variability in patient responses to tamsulosin for lower urinary tract symptoms, suggesting many individuals may benefit from discontinuing the medication. Scott R. Bauer is a medical doctor at the University of California San Francisco.

The study involved 30 men between 55 and 80 years old who had continuously used tamsulosin for at least 12 months. Researchers used a double-blind, placebo-controlled N-of-1 crossover trial design, comparing tamsulosin and a placebo. Participants underwent a week-long placebo run-in period, followed by two blocks of 2-week treatment periods that alternated tamsulosin and placebo, separated by 1-week washout periods. Efficacy was assessed using a modified version of the seven-item American Urological Association Symptom Index.

During the trial, 11 of the 30 patients experienced minimal or no symptom relief from tamsulosin. Another 11 patients showed moderate improvement with the drug. Four patients, representing 13.3% of participants, achieved substantial benefits from tamsulosin. Four other patients could not tolerate the placebo run-in due to worsening symptoms, and the individual-level estimated mean difference in daily AUA-SI score between tamsulosin and placebo ranged from -10.9 to 2.1.

The authors concluded that the study demonstrated heterogeneity in treatment response. Bauer stated, "Specifically, we demonstrated significant heterogeneity in treatment response and identified a significant proportion of participants that may benefit from discontinuing tamsulosin." He added, "This study highlights the need to counsel patients on the heterogeneity of tamsulosin treatment effects and supports the clinical use of empiric tamsulosin trials rather than lifelong therapy." Bauer said, "Larger studies are needed to confirm the generalizability across clinical settings and patient populations, to identify predictors of tamsulosin response, and to test the effect of N-of-1-guided deprescribing on clinical outcomes."

Marco H. Blanker, a medical doctor and PhD at University Medical Center Groningen, said the study was "a great study that, with thanks to its design, was possible to conduct in a small number of participants." Blanker noted, "Although discontinuation of alpha-blocker therapy is advocated for in the Dutch guideline for male LUTS, in daily practice, the discontinuation rate is relatively small."

Why It Matters

Tamsulosin is the most widely prescribed medication for men with lower urinary tract symptoms. Alpha-blockers, such as tamsulosin, carry a risk of adverse events including orthostatic hypotension, dizziness, falls, and fractures. A previous meta-analysis of 10 studies by Dutch investigators examined the discontinuation of alpha-blocker therapy. Data from that meta-analysis indicated that discontinuing alpha-blocker monotherapy resulted in symptom worsening compared to continued treatment, but dropping the alpha-blocker from combination lower urinary tract symptoms treatment did not lead to symptom worsening.